CompletedEUCTR 2008-002247-16
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesSchizophrenia
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Austria · Belgium and 11 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 766
- Sponsor
- Janssen-Cilag International N.V.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Belgium, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2008-002247-16
- Official title
Show the full official title
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedAustria · Belgium · Bulgaria
10 more locations
- Czechia
- Estonia
- France
- Germany
- Greece
- Hungary
- Italy
- Lithuania
- Spain
- United Kingdom
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag International N.V.
